Observational studyPloS one2026
Short-term refractive and corneal astigmatism after canal-based microinvasive glaucoma surgery.
Observational study in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate changes in refractive and corneal astigmatism after Hydrus Microstent (Alcon Inc., Geneva, Switzerland) implantation during microinvasive glaucoma surgery.
settingOne German medical center.
designRetrospective, non-randomized, observational cohort study.
methodsSubjective refraction was obtained mandatorily and keratometry (Pentacam, OCULUS Optikgeräte GmbH, Wetzlar, Germany) optionally preoperatively and after 3 months (D90). Refractive astigmatism was analyzed using three-dimensional (3D) power vectors, including the spherical equivalent, M, the Jackson cross-cylinder projections to the 0° and 90° meridian (J0) and to the 45° and 135° meridian (J45), and the blurring power vector B. Corneal anterior and posterior surface astigmatism was investigated using the vectorial parameters J0, J45, and B. A 3D power vector time-course analysis of refractive astigmatism was performed using multivariate pairwise testing, and linear mixed-effects models, accounting for patient ID as a random effect, were used for the remaining analyses.
resultsA total of 90 ocular hypertension/glaucoma eyes were included. Sixty eyes were implanted with a Hydrus Microstent and phacoemulsified, and 30 eyes underwent implantation as a stand-alone procedure. Univariate analysis of the refractive cylinder showed no variation over time in any cohort (Phacoemulsification: CD0 = -1.3 ± 0.9 D vs. CD90 = -1.2 ± 1.2 D, P = 0.6; Stand-alone: CD0 = -1.6 ± 1.3 D vs. CD90 = -1.6 ± 1.2 D, P = 0.9), and no relevant time-by-group interaction was observed. Multivariate astigmatism analysis (M, J0, J45) indicated a significant change in the phacoemulsification cohort (P = 0.0003), in contrast to the stand-alone procedure cohort (P = 0.5). In the phacoemulsification cohort, B significantly declined from 2.9 ± 2.8 D to 1.2 ± 1.0 D (P < 0.0001) but remained stable in the stand-alone group (2.7 ± 3.5 D to 2.8 ± 3.4 D, P = 0.07). Corneal astigmatism analysis, based on 55 eyes from 37 patients, showed that the magnitudes of the J0 and J45 vectors remained stable over time for both the anterior (D0: J0 = -0.12 ± 0.07 D, D90: J0 = -0.21 ± 0.07 D, P = 0.12; D0: J45 = -0.05 ± 0.05 D, D90: J45 = -0.01 ± 0.05 D, P = 0.5) and posterior surfaces (D0: J0 = 0.12 ± 0.01 D, D90: J0 = 0.13 ± 0.01 D, P = 0.3; D0: J45 = -0.01 ± 0.01 D, D90: J45 = -0.01 ± 0.01 D; P = 0.9), without significant effects of time, group, or their interaction.
conclusionsThe Hydrus Microstent is neutral in refractive astigmatism when used as a stand-alone procedure. In contrast, combined implantation with phacoemulsification can induce changes in refractive astigmatism. Keratometry analysis confirmed that both anterior and posterior corneal astigmatism remain stable, indicating that refractive changes are likely due to internal factors associated with lens exchange rather than the stent itself. Therefore, when implanted alone, the Hydrus Microstent is unlikely to compromise the results of prior refractive treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.